The retail trader's information disadvantage is structural: institutions have proprietary data feeds, legal teams parsing SEC filings, and software monitoring dozens of data sources simultaneously. TraderTools Pro closes that gap with a bundled platform delivering five categories of institutional-grade market intelligence — at a price point built for individual traders.
Buy-and-hold investors can succeed with a brokerage account and quarterly earnings reviews. Active traders — particularly those focused on small and micro-cap stocks where volatility creates the most opportunity — need an entirely different toolset. The information that drives 50–300% moves in small-cap stocks comes from SEC filings, FDA decisions, government contracts, and institutional positioning — not from chart patterns or analyst estimates.
The professional-grade market tools that create an edge in active trading fall into five categories:
In micro and small-cap equities, share dilution is the silent destroyer of trading profits. A company can have a legitimate positive catalyst but still decline if the company issues shares into the rally. Understanding a company's dilution risk — their shelf registration status, ATM program activity, convertible note structure, and warrant schedule — is foundational research for any active trader operating below $500M market cap.
Real-time monitoring of SEC filings for dilution-related events. Every shelf registration, ATM agreement, prospectus supplement, and convertible note filing gets processed as it hits EDGAR and translated into a dilution risk score and alert. Covers thousands of small and micro-cap tickers. The market standard for dilution risk monitoring.
Start Monitoring Dilution →Biotech stocks offer some of the largest percentage moves available to retail traders — but only if you know when the catalyst is coming and have done the research on binary outcome probability. PDUFA dates, Phase 3 readouts, and FDA advisory committee meetings are the events that drive 100%+ single-day moves in small-cap biotech. The traders positioned before the market builds in the catalyst premium capture the most value.
FDA catalyst intelligence platform covering PDUFA dates, clinical trial readouts, breakthrough therapy designations, and advisory committee meetings for hundreds of small and mid-cap biotech companies. Proprietary catalyst scoring synthesizes FDA precedent, clinical data quality, and company financial health into outcome probability estimates. The essential tool for biotech event-driven trading.
Access the Catalyst Calendar →Institutional investors, corporate insiders, and members of Congress are required to publicly disclose their trading activity — but the disclosures are scattered across SEC databases, government websites, and regulatory filings. Aggregating all of these signals into a single real-time feed creates a window into positioning that consistently precedes price moves.
Market intelligence built around mandatory disclosure data — congressional trades, SEC Form 4 insider transactions, institutional 13F filings, dark pool prints, and unusual options activity — aggregated into one real-time wire. The Whisper Index adds social sentiment analysis to identify when retail conviction is building around specific setups, giving you the full picture of who is positioning and why.
Track Smart-Money Flow →Small-cap companies with undisclosed (but SEC-filed) revenue concentration in a single large customer represent both risk and opportunity. When that customer beats earnings or announces capacity expansion, the supplier stock can move dramatically — before any analyst publishes a note on the relationship. ChainSifter maps these relationships from SEC filings so you can find the second-order plays.
Maps supplier-customer relationships and customer concentration risks from SEC material agreement filings and annual report disclosures. Identifies which small-cap stocks are positioned to benefit from specific large-cap earnings events through hidden supply chain exposure. Tracks material agreement changes and contract award filings that signal revenue shifts before quarterly reports confirm them.
Map Supply Chain Relationships →Federal contract awards for publicly traded companies are disclosed publicly on SAM.gov and USASpending.gov the day they're awarded. For defense contractors, government IT services companies, and federal healthcare providers, contract awards — and especially IDIQ task order expansions — are leading revenue indicators that often precede earnings guidance updates by weeks or months.
Monitors federal procurement data for contract awards, modifications, and IDIQ ceiling expansions for publicly traded companies. Filter by ticker, agency, contract type, and dollar threshold to surface only the awards that are material to your holdings. Government contract signals for the stocks where federal revenue is a key driver.
Monitor Government Contracts →TraderTools Pro bundles DilutionWatch, BiotechSigns, StonkWhisper, ChainSifter, and Contract Trader — the complete professional market intelligence stack — at $99/mo locked permanently for Founding Members.
Claim Founding Member RateTraderTools Pro, DilutionWatch, BiotechSigns, StonkWhisper, ChainSifter, and Contract Trader are research platforms providing data for informational and educational purposes only. Nothing on any platform constitutes investment, financial, legal, medical, or procurement advice of any kind. All trading and investment decisions are made solely at your own risk. Past performance is not indicative of future results. · Full Disclaimer · Terms of Service